Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Wells Fargo & Company 

Bio-Rad Labs Inc. A diskutieren

Bio-Rad Labs Inc. A

WKN: 865406 / Symbol: BIO / Name: Bio Rad / Aktie / Ausrüstung & Versorgung / Mid Cap /

307,80 €
-1,96 %

Einschätzung Buy
Rendite (%) -25,32 %
Kursziel 502,10
Veränderung
Endet am 16.06.24

Bio-Rad Laboratories, Inc. (NYSE: BIO) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $550.00 price target on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -15,30 %
Kursziel 474,64
Veränderung
Endet am 04.08.24

Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $522.00 to $524.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -15,63 %
Kursziel 477,33
Veränderung
Endet am 07.08.24

Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Company from $550.00 to $525.00. They now have an "overweight" rating on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,77 %
Kursziel 365,97
Veränderung
Endet am 07.12.24

Bio-Rad Laboratories, Inc. (NYSE: BIO) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $395.00 price target on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,66 %
Kursziel 445,58
Veränderung
Endet am 16.02.25

Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Royal Bank of Canada from $484.00 to $480.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,66 %
Kursziel 389,51
Veränderung
Endet am 16.02.25

Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at UBS Group AG from $395.00 to $420.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) 24,01 %
Kursziel 357,93
Veränderung
Endet am 08.05.25

Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $420.00 to $385.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 367,36
Veränderung
Endet am 02.08.25

Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Royal Bank of Canada from $402.00 to $401.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat